199 related articles for article (PubMed ID: 23763979)
1. D-dimer: a biomarker for antihistamine-resistant chronic urticaria.
Asero R
J Allergy Clin Immunol; 2013 Oct; 132(4):983-6. PubMed ID: 23763979
[No Abstract] [Full Text] [Related]
2. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
3. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
4. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria.
Takahagi S; Mihara S; Iwamoto K; Morioke S; Okabe T; Kameyoshi Y; Hide M
Allergy; 2010 May; 65(5):649-56. PubMed ID: 19845571
[TBL] [Abstract][Full Text] [Related]
5. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
Asero R; Tedeschi A; Cugno M
Int Arch Allergy Immunol; 2010; 152(4):384-9. PubMed ID: 20203527
[TBL] [Abstract][Full Text] [Related]
6. Four cases of acute infectious urticaria showing significant elevation of plasma D-dimer level.
Takahashi T; Minami S; Teramura K; Tanaka T; Fujimoto N
J Dermatol; 2018 Aug; 45(8):1013-1016. PubMed ID: 29797525
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
[No Abstract] [Full Text] [Related]
9. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
10. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy.
Krause K; Ardelean E; Kessler B; Magerl M; Metz M; Siebenhaar F; Weller K; Worm M; Zuberbier T; Maurer M
Allergy; 2010 Nov; 65(11):1494-5. PubMed ID: 20560911
[No Abstract] [Full Text] [Related]
11. Clinical efficacy of reserpine as "add-on therapy" to antihistamines in patients with recalcitrant chronic idiopathic urticaria and urticarial vasculitis.
Demitsu T; Yoneda K; Kakurai M; Sasaki K; Hiratsuka Y; Azuma R; Yamada T; Umemoto N
J Dermatol; 2010 Sep; 37(9):827-9. PubMed ID: 20883370
[No Abstract] [Full Text] [Related]
12. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis.
Asero R; Tedeschi A
J Investig Allergol Clin Immunol; 2010; 20(5):386-90. PubMed ID: 20945604
[TBL] [Abstract][Full Text] [Related]
13. Severity of acute and chronic urticaria correlates with D-dimer level, but not C-reactive protein or total IgE.
Baek YS; Jeon J; Kim JH; Oh CH
Clin Exp Dermatol; 2014 Oct; 39(7):795-800. PubMed ID: 25196271
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
15. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
Lang DM
Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
[No Abstract] [Full Text] [Related]
16. Successful treatment of solar urticaria with anti-immunoglobulin E therapy.
Güzelbey O; Ardelean E; Magerl M; Zuberbier T; Maurer M; Metz M
Allergy; 2008 Nov; 63(11):1563-5. PubMed ID: 18925897
[No Abstract] [Full Text] [Related]
17. Possible benefit from treatment of Helicobacter pylori in antihistamine-resistant chronic urticaria.
Magen E; Mishal J
Clin Exp Dermatol; 2013 Jan; 38(1):7-12. PubMed ID: 23083221
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of atorvastatin and antihistamines in comparison with antihistamines plus placebo in the treatment of chronic idiopathic urticaria: a controlled clinical trial.
Pezeshkpoor F; Farid Hosseini R; Rafatpanah H; Shakerian B; Jabbari F; Zandkarimi MR; Yousefzadeh H; Sadri H; Bahrami A; Zamani MA
Iran J Allergy Asthma Immunol; 2012 Sep; 11(3):236-40. PubMed ID: 22947909
[TBL] [Abstract][Full Text] [Related]
20. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU.
Asero R; Marzano AV; Ferrucci S; Cugno M
J Allergy Clin Immunol Pract; 2017; 5(6):1740-1742. PubMed ID: 28866106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
